nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Gallbladder disorder—Varenicline—nicotine dependence	0.107	0.154	CcSEcCtD
Darifenacin—Depressed mood—Varenicline—nicotine dependence	0.0393	0.0565	CcSEcCtD
Darifenacin—Accidental injury—Varenicline—nicotine dependence	0.0198	0.0286	CcSEcCtD
Darifenacin—Thinking abnormal—Varenicline—nicotine dependence	0.0192	0.0276	CcSEcCtD
Darifenacin—Dry eye—Varenicline—nicotine dependence	0.0162	0.0233	CcSEcCtD
Darifenacin—Mouth ulceration—Varenicline—nicotine dependence	0.0159	0.0228	CcSEcCtD
Darifenacin—Mental disability—Varenicline—nicotine dependence	0.0152	0.0219	CcSEcCtD
Darifenacin—Injury—Varenicline—nicotine dependence	0.0139	0.02	CcSEcCtD
Darifenacin—Visual disturbance—Varenicline—nicotine dependence	0.0134	0.0194	CcSEcCtD
Darifenacin—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0133	0.0518	CbGpPWpGaD
Darifenacin—Cerebrovascular accident—Varenicline—nicotine dependence	0.013	0.0187	CcSEcCtD
Darifenacin—Urinary retention—Varenicline—nicotine dependence	0.0121	0.0174	CcSEcCtD
Darifenacin—Dry skin—Varenicline—nicotine dependence	0.0117	0.0168	CcSEcCtD
Darifenacin—Breast disorder—Varenicline—nicotine dependence	0.0115	0.0166	CcSEcCtD
Darifenacin—Difenoxin—OPRM1—nicotine dependence	0.0114	0.237	CrCbGaD
Darifenacin—Anileridine—OPRM1—nicotine dependence	0.0111	0.231	CrCbGaD
Darifenacin—Bronchitis—Varenicline—nicotine dependence	0.0106	0.0152	CcSEcCtD
Darifenacin—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0104	0.0404	CbGpPWpGaD
Darifenacin—Erectile dysfunction—Varenicline—nicotine dependence	0.0101	0.0146	CcSEcCtD
Darifenacin—Weight increased—Varenicline—nicotine dependence	0.01	0.0144	CcSEcCtD
Darifenacin—Infestation NOS—Varenicline—nicotine dependence	0.00982	0.0141	CcSEcCtD
Darifenacin—Infestation—Varenicline—nicotine dependence	0.00982	0.0141	CcSEcCtD
Darifenacin—Stomatitis—Varenicline—nicotine dependence	0.00957	0.0138	CcSEcCtD
Darifenacin—Sinusitis—Varenicline—nicotine dependence	0.00921	0.0133	CcSEcCtD
Darifenacin—Hallucination—Varenicline—nicotine dependence	0.00877	0.0126	CcSEcCtD
Darifenacin—Urinary tract disorder—Varenicline—nicotine dependence	0.0087	0.0125	CcSEcCtD
Darifenacin—Oedema peripheral—Varenicline—nicotine dependence	0.00868	0.0125	CcSEcCtD
Darifenacin—Urethral disorder—Varenicline—nicotine dependence	0.00864	0.0124	CcSEcCtD
Darifenacin—Visual impairment—Varenicline—nicotine dependence	0.00849	0.0122	CcSEcCtD
Darifenacin—Methadone—CHRNA10—nicotine dependence	0.00839	0.174	CrCbGaD
Darifenacin—Erythema multiforme—Varenicline—nicotine dependence	0.00833	0.012	CcSEcCtD
Darifenacin—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00826	0.0321	CbGpPWpGaD
Darifenacin—Eye disorder—Varenicline—nicotine dependence	0.00824	0.0119	CcSEcCtD
Darifenacin—Diphenoxylate—OPRM1—nicotine dependence	0.00805	0.167	CrCbGaD
Darifenacin—Angiopathy—Varenicline—nicotine dependence	0.008	0.0115	CcSEcCtD
Darifenacin—Mediastinal disorder—Varenicline—nicotine dependence	0.00794	0.0114	CcSEcCtD
Darifenacin—Mental disorder—Varenicline—nicotine dependence	0.00772	0.0111	CcSEcCtD
Darifenacin—Flatulence—Varenicline—nicotine dependence	0.00756	0.0109	CcSEcCtD
Darifenacin—Dysgeusia—Varenicline—nicotine dependence	0.00751	0.0108	CcSEcCtD
Darifenacin—Back pain—Varenicline—nicotine dependence	0.00742	0.0107	CcSEcCtD
Darifenacin—Vision blurred—Varenicline—nicotine dependence	0.00723	0.0104	CcSEcCtD
Darifenacin—Angioedema—Varenicline—nicotine dependence	0.00701	0.0101	CcSEcCtD
Darifenacin—Syncope—Varenicline—nicotine dependence	0.00688	0.0099	CcSEcCtD
Darifenacin—Palpitations—Varenicline—nicotine dependence	0.00678	0.00976	CcSEcCtD
Darifenacin—Loss of consciousness—Varenicline—nicotine dependence	0.00674	0.00971	CcSEcCtD
Darifenacin—Cough—Varenicline—nicotine dependence	0.0067	0.00964	CcSEcCtD
Darifenacin—Hypertension—Varenicline—nicotine dependence	0.00662	0.00953	CcSEcCtD
Darifenacin—Arthralgia—Varenicline—nicotine dependence	0.00653	0.0094	CcSEcCtD
Darifenacin—CHRM4—Monoamine GPCRs—DRD2—nicotine dependence	0.00651	0.0253	CbGpPWpGaD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00649	0.00934	CcSEcCtD
Darifenacin—Dry mouth—Varenicline—nicotine dependence	0.00639	0.0092	CcSEcCtD
Darifenacin—Oedema—Varenicline—nicotine dependence	0.00626	0.00901	CcSEcCtD
Darifenacin—CHRM5—Monoamine GPCRs—DRD2—nicotine dependence	0.00623	0.0242	CbGpPWpGaD
Darifenacin—Infection—Varenicline—nicotine dependence	0.00622	0.00895	CcSEcCtD
Darifenacin—Shock—Varenicline—nicotine dependence	0.00616	0.00887	CcSEcCtD
Darifenacin—Nervous system disorder—Varenicline—nicotine dependence	0.00614	0.00884	CcSEcCtD
Darifenacin—Tachycardia—Varenicline—nicotine dependence	0.00611	0.0088	CcSEcCtD
Darifenacin—Skin disorder—Varenicline—nicotine dependence	0.00608	0.00875	CcSEcCtD
Darifenacin—Hyperhidrosis—Varenicline—nicotine dependence	0.00605	0.00871	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00571	0.00821	CcSEcCtD
Darifenacin—Insomnia—Varenicline—nicotine dependence	0.00566	0.00815	CcSEcCtD
Darifenacin—Dyspnoea—Varenicline—nicotine dependence	0.00558	0.00804	CcSEcCtD
Darifenacin—Somnolence—Varenicline—nicotine dependence	0.00557	0.00801	CcSEcCtD
Darifenacin—Dyspepsia—Varenicline—nicotine dependence	0.00551	0.00793	CcSEcCtD
Darifenacin—CHRM4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00547	0.0213	CbGpPWpGaD
Darifenacin—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00541	0.00778	CcSEcCtD
Darifenacin—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.0054	0.021	CbGpPWpGaD
Darifenacin—Pain—Varenicline—nicotine dependence	0.00536	0.00771	CcSEcCtD
Darifenacin—Constipation—Varenicline—nicotine dependence	0.00536	0.00771	CcSEcCtD
Darifenacin—CHRM5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00524	0.0204	CbGpPWpGaD
Darifenacin—Feeling abnormal—Varenicline—nicotine dependence	0.00516	0.00743	CcSEcCtD
Darifenacin—Gastrointestinal pain—Varenicline—nicotine dependence	0.00512	0.00737	CcSEcCtD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00502	0.0195	CbGpPWpGaD
Darifenacin—Abdominal pain—Varenicline—nicotine dependence	0.00495	0.00713	CcSEcCtD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0048	0.0187	CbGpPWpGaD
Darifenacin—Hypersensitivity—Varenicline—nicotine dependence	0.00461	0.00664	CcSEcCtD
Darifenacin—Asthenia—Varenicline—nicotine dependence	0.00449	0.00647	CcSEcCtD
Darifenacin—CHRM4—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00444	0.0173	CbGpPWpGaD
Darifenacin—Pruritus—Varenicline—nicotine dependence	0.00443	0.00638	CcSEcCtD
Darifenacin—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.00439	0.0171	CbGpPWpGaD
Darifenacin—CHRM3—Monoamine GPCRs—DRD2—nicotine dependence	0.00437	0.017	CbGpPWpGaD
Darifenacin—CHRM2—Monoamine GPCRs—DRD2—nicotine dependence	0.00433	0.0169	CbGpPWpGaD
Darifenacin—Diarrhoea—Varenicline—nicotine dependence	0.00428	0.00617	CcSEcCtD
Darifenacin—Dizziness—Varenicline—nicotine dependence	0.00414	0.00596	CcSEcCtD
Darifenacin—Vomiting—Varenicline—nicotine dependence	0.00398	0.00573	CcSEcCtD
Darifenacin—Rash—Varenicline—nicotine dependence	0.00395	0.00568	CcSEcCtD
Darifenacin—Dermatitis—Varenicline—nicotine dependence	0.00394	0.00568	CcSEcCtD
Darifenacin—Headache—Varenicline—nicotine dependence	0.00392	0.00565	CcSEcCtD
Darifenacin—Nausea—Varenicline—nicotine dependence	0.00372	0.00535	CcSEcCtD
Darifenacin—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00369	0.0144	CbGpPWpGaD
Darifenacin—CHRM3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00368	0.0143	CbGpPWpGaD
Darifenacin—CHRM2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00364	0.0142	CbGpPWpGaD
Darifenacin—Fentanyl—OPRM1—nicotine dependence	0.00347	0.0719	CrCbGaD
Darifenacin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00343	0.0133	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00338	0.0132	CbGpPWpGaD
Darifenacin—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00338	0.0132	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00337	0.0131	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00334	0.013	CbGpPWpGaD
Darifenacin—Loperamide—OPRM1—nicotine dependence	0.00334	0.0693	CrCbGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00312	0.0121	CbGpPWpGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00299	0.0116	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00299	0.0116	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00296	0.0115	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00287	0.0112	CbGpPWpGaD
Darifenacin—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00278	0.0108	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—TAS2R16—nicotine dependence	0.00269	0.0105	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—TAS2R16—nicotine dependence	0.00257	0.01	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00253	0.00986	CbGpPWpGaD
Darifenacin—Methadone—OPRM1—nicotine dependence	0.00238	0.0493	CrCbGaD
Darifenacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00224	0.00872	CbGpPWpGaD
Darifenacin—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00221	0.0086	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00211	0.00819	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.0021	0.00816	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00208	0.00809	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00202	0.00785	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00201	0.00783	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00199	0.00775	CbGpPWpGaD
Darifenacin—CHRM4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00187	0.00728	CbGpPWpGaD
Darifenacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00182	0.00707	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00181	0.00705	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—TAS2R16—nicotine dependence	0.00181	0.00703	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00179	0.00696	CbGpPWpGaD
Darifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00174	0.00676	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00169	0.00658	CbGpPWpGaD
Darifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00166	0.00647	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00157	0.00609	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00154	0.00597	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00152	0.00591	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00149	0.00579	CbGpPWpGaD
Darifenacin—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00148	0.00574	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00146	0.00566	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00146	0.00566	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00143	0.00555	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.0014	0.00544	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—TAS2R16—nicotine dependence	0.00138	0.00537	CbGpPWpGaD
Darifenacin—CHRM4—G alpha (i) signalling events—DRD2—nicotine dependence	0.00135	0.00527	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—TAS2R16—nicotine dependence	0.00132	0.00514	CbGpPWpGaD
Darifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00126	0.00489	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00125	0.00485	CbGpPWpGaD
Darifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.0012	0.00468	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—FGD1—nicotine dependence	0.00119	0.00464	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00117	0.00456	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00117	0.00454	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00116	0.0045	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—FGD1—nicotine dependence	0.00114	0.00444	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—OPRM1—nicotine dependence	0.00113	0.00441	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—OPRM1—nicotine dependence	0.00109	0.00422	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—FGD1—nicotine dependence	0.00108	0.00421	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00108	0.00419	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—FGD1—nicotine dependence	0.00104	0.00403	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	0.00103	0.00402	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00103	0.00401	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00102	0.00399	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00102	0.00398	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00102	0.00397	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00101	0.00393	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.001	0.0039	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.001	0.00389	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000991	0.00385	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000965	0.00375	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000952	0.0037	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00093	0.00362	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000927	0.00361	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000918	0.00357	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—DRD2—nicotine dependence	0.000901	0.0035	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000847	0.00329	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000844	0.00328	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000836	0.00325	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—DRD2—nicotine dependence	0.000819	0.00319	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TAS2R16—nicotine dependence	0.000815	0.00317	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.000804	0.00313	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—FGD1—nicotine dependence	0.000801	0.00312	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—FGD1—nicotine dependence	0.000794	0.00309	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—DRD2—nicotine dependence	0.000785	0.00305	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TAS2R16—nicotine dependence	0.000781	0.00304	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	0.000764	0.00297	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—OPRM1—nicotine dependence	0.000762	0.00296	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—OPRM1—nicotine dependence	0.000754	0.00293	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	0.00073	0.00284	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—FGD1—nicotine dependence	0.000728	0.00283	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000726	0.00282	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000723	0.00281	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—FGD1—nicotine dependence	0.000721	0.0028	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000716	0.00279	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—OPRM1—nicotine dependence	0.000641	0.00249	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—FGD1—nicotine dependence	0.00064	0.00249	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—OPRM1—nicotine dependence	0.000613	0.00239	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—FGD1—nicotine dependence	0.000613	0.00238	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—OPRM1—nicotine dependence	0.000582	0.00226	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKR1B10—nicotine dependence	0.000565	0.0022	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—OPRM1—nicotine dependence	0.000557	0.00217	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	0.000553	0.00215	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—DRD2—nicotine dependence	0.000551	0.00214	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.00055	0.00214	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TAS2R16—nicotine dependence	0.000548	0.00213	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—DRD2—nicotine dependence	0.000545	0.00212	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TAS2R16—nicotine dependence	0.000543	0.00211	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKR1B10—nicotine dependence	0.000541	0.0021	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—DRD2—nicotine dependence	0.000463	0.0018	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—DRD2—nicotine dependence	0.000443	0.00173	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000432	0.00168	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—FGD1—nicotine dependence	0.000431	0.00168	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—OPRM1—nicotine dependence	0.000431	0.00167	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—FGD1—nicotine dependence	0.00043	0.00167	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—OPRM1—nicotine dependence	0.000426	0.00166	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—FGD1—nicotine dependence	0.000426	0.00166	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP2A7—nicotine dependence	0.000422	0.00164	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—DRD2—nicotine dependence	0.000421	0.00164	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—DRD2—nicotine dependence	0.000403	0.00157	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—WASF2—nicotine dependence	0.000398	0.00155	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	0.000392	0.00153	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—OPRM1—nicotine dependence	0.000391	0.00152	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—OPRM1—nicotine dependence	0.000387	0.00151	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—WASF1—nicotine dependence	0.000382	0.00148	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—WASF2—nicotine dependence	0.000381	0.00148	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	0.000381	0.00148	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKR1B10—nicotine dependence	0.00038	0.00148	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKR1B10—nicotine dependence	0.000376	0.00146	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—WASF1—nicotine dependence	0.000365	0.00142	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—OPRM1—nicotine dependence	0.000344	0.00134	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—OPRM1—nicotine dependence	0.000329	0.00128	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	0.000312	0.00121	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—DRD2—nicotine dependence	0.000311	0.00121	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—DRD2—nicotine dependence	0.000308	0.0012	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	0.000284	0.0011	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—DRD2—nicotine dependence	0.000283	0.0011	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—DRD2—nicotine dependence	0.00028	0.00109	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—WASF2—nicotine dependence	0.000268	0.00104	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—WASF2—nicotine dependence	0.000268	0.00104	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—WASF2—nicotine dependence	0.000265	0.00103	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—WASF1—nicotine dependence	0.000257	0.001	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—WASF1—nicotine dependence	0.000257	0.000998	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—WASF1—nicotine dependence	0.000254	0.000988	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000252	0.000982	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—DRD2—nicotine dependence	0.000248	0.000966	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—DRD2—nicotine dependence	0.000238	0.000925	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	0.000232	0.000901	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—OPRM1—nicotine dependence	0.000231	0.000898	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—OPRM1—nicotine dependence	0.000229	0.00089	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—DRD2—nicotine dependence	0.000168	0.000652	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—DRD2—nicotine dependence	0.000167	0.00065	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—DRD2—nicotine dependence	0.000165	0.000643	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000165	0.000642	CbGpPWpGaD
